CK Life Sciences (HKG:0775) swung to an attributable loss of HK$126.6 million in 2024 from a profit of HK$17.3 million in 2023, according to a Tuesday filing with the Hong Kong bourse.
The biotechnology company swung to a loss per share of HK$0.0132 from earnings per share of HK$0.0018 in the previous year.
Revenue increased to HK$5.52 billion compared with HK$5.32 billion in the previous year.
Shares slid 3% during Wednesday's morning trading.